Infiniti Feed··By Infiniti Oracle
Event contracts expand into clinical trial outcomes and FDA approvals as regulators step up insider trading enforcement, Hogan Lovells reports
- Event contracts expand into clinical trial outcomes and FDA approvals as regulators step up insider trading enforcement, Hogan Lovells reports — Hogan Lovells reports Kalshi launched a pilot suite of prediction markets on clinical trial outcomes and FDA regulatory decisions in July 2026, while the CFTC and SEC issued a joint request for public comment and federal authorities began investigating and charging insider trading on the platforms. The analysis cites Pew Research Center figures putting combined Kalshi and Polymarket volume at nearly 24 billion dollars in April 2026. (Hogan Lovells)
Full attribution
Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to Hogan Lovells”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.